Change of number of shares and votes in Karolinska Development

STOCKHOLM - October 30, 2015. The number of series B shares in Karolinska Development AB (Nasdaq Stockholm: KDEV) has increased by 65,082 shares via the allotment of shares to participants in the share-based incentive program (PSP 2012) that was decided by the Annual General Meeting in 2012.

Today, the last trading day of the month, there are in total 53,449,640 shares outstanding which in total have 66,977,522 votes in Karolinska Development. Of these, 1,503,098 are series A shares with 15,030,980 votes and 51,946,542 B shares with one vote each.

For further information, please contact:

Jim Van heusden, CEO, Karolinska Development AB Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB is an investment company focused on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of 12 companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team including investment professionals with strong venture capital backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

This constitutes information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is legally obliged to publish under the Securities Market Act and/or the Financial Instruments Trading Act.